An ELISA Platform for the Quantitative Analysis of SARS-CoV-2 RBD-neutralizing Antibodies As an Alternative to Monitoring of the Virus-Neutralizing Activity

N. N. Kostin; T. V. Bobik; G. A. Skryabin; M. A. Simonova; V. D. Knorre; V. A. Abrikosova; Y. A. Mokrushina; I. V. Smirnov; N. L. Aleshenko; N. A. Kruglova; D. V. Mazurov; A. E. Nikitin; A. G. Gabibov

doi:10.32607/actanaturae.11776

An ELISA Platform for the Quantitative Analysis of SARS-CoV-2 RBD-neutralizing Antibodies As an Alternative to Monitoring of the Virus-Neutralizing Activity

N. N. Kostin, T. V. Bobik, G. A. Skryabin, M. A. Simonova, V. D. Knorre, V. A. Abrikosova, Y. A. Mokrushina, I. V. Smirnov, N. L. Aleshenko, N. A. Kruglova, D. V. Mazurov, A. E. Nikitin, A. G. Gabibov

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Monitoring of the level of the virus-neutralizing activity of serum immunoglobulins ensures that one can reliably assess the effectiveness of any protection against the SARS-CoV-2 infection. For SARS-CoV-2, the RBD-ACE2 neutralizing activity of sera is almost equivalent to the virus-neutralizing activity of their antibodies and can be used to assess the level of SARS-CoV-2 neutralizing antibodies. We are proposing an ELISA platform for performing a quantitative analysis of SARS-CoV-2 RBD-neutralizing antibodies, as an alternative to the monitoring of the virus-neutralizing activity using pseudovirus or “live” virus assays. The advantage of the developed platform is that it can be adapted to newly emerging virus variants in a very short time (1–2 weeks) and, thereby, provide quantitative data on the activity of SARS-CoV-2 RBDneutralizing antibodies. The developed platform can be used to (1) study herd immunity to SARS-CoV-2, (2) monitor the effectiveness of the vaccination drive (revaccination) in a population, and (3) select potential donors of immune plasma. The protective properties of the humoral immune response in hospitalized patients and outpatients, as well as after prophylaxis with the two most popular SARS-CoV-2 vaccines in Russia, were studied in detail using this platform. The highest RBD-neutralizing activity was observed in the group of hospitalized patients. The protective effect in the group of individuals vaccinated with Gam-COVID-Vac vaccine was 25% higher than that in outpatients and almost four times higher than that in individuals vaccinated with the CoviVac vaccine.

Original language	English (US)
Pages (from-to)	109-119
Number of pages	11
Journal	Acta Naturae
Volume	14
Issue number	3
DOIs	https://doi.org/10.32607/actanaturae.11776
State	Published - 2022
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2022 National Research University Higher School of Economics. This is an open access article distributed under the Creative Commons Attribution License,which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Keywords

Antibodies
Covid-19
Covivac
Gam-covid-vac
Sars-cov-2
Sputnik v
Virus-neutralizing activity

PubMed: MeSH publication types

Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.32607/actanaturae.11776

Find It

Find It at U of M Libraries

Cite this

Kostin, N. N., Bobik, T. V., Skryabin, G. A., Simonova, M. A., Knorre, V. D., Abrikosova, V. A., Mokrushina, Y. A., Smirnov, I. V., Aleshenko, N. L., Kruglova, N. A., Mazurov, D. V., Nikitin, A. E., & Gabibov, A. G. (2022). An ELISA Platform for the Quantitative Analysis of SARS-CoV-2 RBD-neutralizing Antibodies As an Alternative to Monitoring of the Virus-Neutralizing Activity. Acta Naturae, 14(3), 109-119. https://doi.org/10.32607/actanaturae.11776

Kostin, NN, Bobik, TV, Skryabin, GA, Simonova, MA, Knorre, VD, Abrikosova, VA, Mokrushina, YA, Smirnov, IV, Aleshenko, NL, Kruglova, NA, Mazurov, DV, Nikitin, AE & Gabibov, AG 2022, 'An ELISA Platform for the Quantitative Analysis of SARS-CoV-2 RBD-neutralizing Antibodies As an Alternative to Monitoring of the Virus-Neutralizing Activity', Acta Naturae, vol. 14, no. 3, pp. 109-119. https://doi.org/10.32607/actanaturae.11776

@article{5f2229c1b9604b39aedaebfc1cdcd203,

title = "An ELISA Platform for the Quantitative Analysis of SARS-CoV-2 RBD-neutralizing Antibodies As an Alternative to Monitoring of the Virus-Neutralizing Activity",

abstract = "Monitoring of the level of the virus-neutralizing activity of serum immunoglobulins ensures that one can reliably assess the effectiveness of any protection against the SARS-CoV-2 infection. For SARS-CoV-2, the RBD-ACE2 neutralizing activity of sera is almost equivalent to the virus-neutralizing activity of their antibodies and can be used to assess the level of SARS-CoV-2 neutralizing antibodies. We are proposing an ELISA platform for performing a quantitative analysis of SARS-CoV-2 RBD-neutralizing antibodies, as an alternative to the monitoring of the virus-neutralizing activity using pseudovirus or “live” virus assays. The advantage of the developed platform is that it can be adapted to newly emerging virus variants in a very short time (1–2 weeks) and, thereby, provide quantitative data on the activity of SARS-CoV-2 RBDneutralizing antibodies. The developed platform can be used to (1) study herd immunity to SARS-CoV-2, (2) monitor the effectiveness of the vaccination drive (revaccination) in a population, and (3) select potential donors of immune plasma. The protective properties of the humoral immune response in hospitalized patients and outpatients, as well as after prophylaxis with the two most popular SARS-CoV-2 vaccines in Russia, were studied in detail using this platform. The highest RBD-neutralizing activity was observed in the group of hospitalized patients. The protective effect in the group of individuals vaccinated with Gam-COVID-Vac vaccine was 25% higher than that in outpatients and almost four times higher than that in individuals vaccinated with the CoviVac vaccine.",

keywords = "Antibodies, Covid-19, Covivac, Gam-covid-vac, Sars-cov-2, Sputnik v, Virus-neutralizing activity",

author = "Kostin, {N. N.} and Bobik, {T. V.} and Skryabin, {G. A.} and Simonova, {M. A.} and Knorre, {V. D.} and Abrikosova, {V. A.} and Mokrushina, {Y. A.} and Smirnov, {I. V.} and Aleshenko, {N. L.} and Kruglova, {N. A.} and Mazurov, {D. V.} and Nikitin, {A. E.} and Gabibov, {A. G.}",

note = "Publisher Copyright: {\textcopyright} 2022 National Research University Higher School of Economics. This is an open access article distributed under the Creative Commons Attribution License,which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.",

year = "2022",

doi = "10.32607/actanaturae.11776",

language = "English (US)",

volume = "14",

pages = "109--119",

journal = "Acta Naturae",

issn = "2075-8251",

publisher = "Acta Naturae",

number = "3",

}

TY - JOUR

T1 - An ELISA Platform for the Quantitative Analysis of SARS-CoV-2 RBD-neutralizing Antibodies As an Alternative to Monitoring of the Virus-Neutralizing Activity

AU - Kostin, N. N.

AU - Bobik, T. V.

AU - Skryabin, G. A.

AU - Simonova, M. A.

AU - Knorre, V. D.

AU - Abrikosova, V. A.

AU - Mokrushina, Y. A.

AU - Smirnov, I. V.

AU - Aleshenko, N. L.

AU - Kruglova, N. A.

AU - Mazurov, D. V.

AU - Nikitin, A. E.

AU - Gabibov, A. G.

N1 - Publisher Copyright: © 2022 National Research University Higher School of Economics. This is an open access article distributed under the Creative Commons Attribution License,which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PY - 2022

Y1 - 2022

N2 - Monitoring of the level of the virus-neutralizing activity of serum immunoglobulins ensures that one can reliably assess the effectiveness of any protection against the SARS-CoV-2 infection. For SARS-CoV-2, the RBD-ACE2 neutralizing activity of sera is almost equivalent to the virus-neutralizing activity of their antibodies and can be used to assess the level of SARS-CoV-2 neutralizing antibodies. We are proposing an ELISA platform for performing a quantitative analysis of SARS-CoV-2 RBD-neutralizing antibodies, as an alternative to the monitoring of the virus-neutralizing activity using pseudovirus or “live” virus assays. The advantage of the developed platform is that it can be adapted to newly emerging virus variants in a very short time (1–2 weeks) and, thereby, provide quantitative data on the activity of SARS-CoV-2 RBDneutralizing antibodies. The developed platform can be used to (1) study herd immunity to SARS-CoV-2, (2) monitor the effectiveness of the vaccination drive (revaccination) in a population, and (3) select potential donors of immune plasma. The protective properties of the humoral immune response in hospitalized patients and outpatients, as well as after prophylaxis with the two most popular SARS-CoV-2 vaccines in Russia, were studied in detail using this platform. The highest RBD-neutralizing activity was observed in the group of hospitalized patients. The protective effect in the group of individuals vaccinated with Gam-COVID-Vac vaccine was 25% higher than that in outpatients and almost four times higher than that in individuals vaccinated with the CoviVac vaccine.

AB - Monitoring of the level of the virus-neutralizing activity of serum immunoglobulins ensures that one can reliably assess the effectiveness of any protection against the SARS-CoV-2 infection. For SARS-CoV-2, the RBD-ACE2 neutralizing activity of sera is almost equivalent to the virus-neutralizing activity of their antibodies and can be used to assess the level of SARS-CoV-2 neutralizing antibodies. We are proposing an ELISA platform for performing a quantitative analysis of SARS-CoV-2 RBD-neutralizing antibodies, as an alternative to the monitoring of the virus-neutralizing activity using pseudovirus or “live” virus assays. The advantage of the developed platform is that it can be adapted to newly emerging virus variants in a very short time (1–2 weeks) and, thereby, provide quantitative data on the activity of SARS-CoV-2 RBDneutralizing antibodies. The developed platform can be used to (1) study herd immunity to SARS-CoV-2, (2) monitor the effectiveness of the vaccination drive (revaccination) in a population, and (3) select potential donors of immune plasma. The protective properties of the humoral immune response in hospitalized patients and outpatients, as well as after prophylaxis with the two most popular SARS-CoV-2 vaccines in Russia, were studied in detail using this platform. The highest RBD-neutralizing activity was observed in the group of hospitalized patients. The protective effect in the group of individuals vaccinated with Gam-COVID-Vac vaccine was 25% higher than that in outpatients and almost four times higher than that in individuals vaccinated with the CoviVac vaccine.

KW - Antibodies

KW - Covid-19

KW - Covivac

KW - Gam-covid-vac

KW - Sars-cov-2

KW - Sputnik v

KW - Virus-neutralizing activity

UR - http://www.scopus.com/inward/record.url?scp=85141755401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85141755401&partnerID=8YFLogxK

U2 - 10.32607/actanaturae.11776

DO - 10.32607/actanaturae.11776

M3 - Article

C2 - 36348715

AN - SCOPUS:85141755401

SN - 2075-8251

VL - 14

SP - 109

EP - 119

JO - Acta Naturae

JF - Acta Naturae

IS - 3

ER -

An ELISA Platform for the Quantitative Analysis of SARS-CoV-2 RBD-neutralizing Antibodies As an Alternative to Monitoring of the Virus-Neutralizing Activity

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this